Claudin-5 and inflammatory biomarkers in panic disorder
A 6-week follow-up study
Bibliographic Data
| ID | 15522366 |
|---|---|
| Authors | Dilek Örüm (Elazığ Eğitim ve Araştırma Hastanesi, corresponding author), Zekiye Çatak (0000-0003-1973-3645, Elazığ Eğitim ve Araştırma Hastanesi), Ali Baran Tanrıkulu (0000-0002-3484-1516, Elazığ Eğitim ve Araştırma Hastanesi), Murad Atmaca (0000-0003-2772-4124, Elazığ Eğitim ve Araştırma Hastanesi) |
| Year | 2025 |
| Volume | 16 |
| Pages | 1703509-1703509 |
| Publication date | 2025-12-11 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Psychiatry (JOURNAL) |
| Journal identifiers | ISSN: 1664-0640 • E-ISSN: 1664-0640 |
| Publisher | Frontiers Media (PUBLISHER • CH) |
| DOI | 10.3389/fpsyt.2025.1703509 |
| PMID | 41458033 |
| OpenAlex | W4417221125 |
| Language | EN |
| References cited | 22 |
In subjects presenting with PD symptoms, increased parameters that may be associated with increased inflammation (such as CRP, CRP/albumin ratio, and neutrophil count), along with claudin-5 levels and the association between them, and the decrease in claudin-5 levels after a 6-week follow-up following a decrease in PD symptom severity, suggest that alterations in claudin-5 level in PD may be related to PD symptomatology. The high level of claudin-5 at the initial clinical presentation may be explained as a direct consequence of neuroinflammation in PD and/or as a compensatory change that occurs secondary to the neuroinflammation in PD. It can be assumed that as PD symptom severity decreases, neuroinflammation decreases, and claudin-5 production slows down
Biomarker · Immune system · Inflammation · Neuroinflammation · Panic · Panic disorder · Barrier Structure and Function Studies · Neuroinflammation and Neurodegeneration Mechanisms · Tryptophan and brain disorders
| Citation velocity | historical |
|---|---|
| Highly cited | No |